Clinical Trial Update: Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MDX-010 (ipilimumab) alone and with docetaxel in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• MDX-010 (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED